Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.73 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.73 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14258672 | 0.91 | AGTR1 (0.72) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL10109219 | 0.91 | AGTR1 (0.72) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL27937302 | 0.88 | AGTR1 (0.69) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL991977 | 0.88 | AGTR1 (0.69) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL8204271 | 0.85 | AGTR1 (0.69) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL787257 | 0.84 | AGTR2 (0.78) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan SCHEMBL677160 | 0.84 | AGTR1 (1.00) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL684085 | 0.84 | AGTR1 (0.71) | AGTR1AGTR2 | |
| SCHEMBL16872178 | 0.83 | AGTR1 (0.62) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL8262045 | 0.83 | AGTR1 (0.62) | AGTR1AGTR2ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102079-A1 | ACETONE SOLVATE CRYSTALS OF TRITYL OMESARTAN MEDOXOMIL | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-04-14 | — | — | US | disclosed |
| US-8933241-B2 | Method for producing olmesartan medoxomil | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8859600-B2 | Acetone solvate crystals of trityl olmesartan medoxomil | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-10-14 | — | — | US | disclosed |
| WO-2008097546-A2 | COMPOUNDS THAT INHIBIT CHOLINESTERASE | COLUCID PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102079-A1 | ACETONE SOLVATE CRYSTALS OF TRITYL OMESARTAN MEDOXOMIL | THOP1, MSMO1, HAAO | AGTR1 23/4885AGTR2 29/4885ABCC3 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.